The BRAAVE2020 study investigated the efficacy of switching Black Americans living with HIV to a B/F/TAF single-pill regimen.

Foster City, Calif.-based Gilead (GILD) had net income of $1.25 billion, or $1.00 a share, for the quarter, down from $2.18 billion, or $1.73 a share, in the year-earlier period. Adjusted for one-time ...

Secured multi-regional patent assets, strengthening Ainos' AI Nose technology. Expanded VELDONA® patent portfolio with a new invention patent for treatments and preventions for coronavirus infections.

Gilead Sciences posted higher revenue and raised its full-year outlook due to strong demand in the third quarter. The biopharmaceutical company on Wednesday reported third quarter net income of $1.25 ...

Other Trump supporters who could be considered for Cabinet positions are former Republican presidential candidate Vivek ...

Gilead Sciences easily beat third-quarter forecasts late Wednesday, and raised its outlook in a move that could bolster ...